• (1R,2R,5S)-8-Methyl-8-azabicyclo[3.2.1]oct-2-yl hydroxy(diphenyl)acetate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass351.446 g·mol−1
3D model (JSmol)
  • CN1C2CC[C@H](C1CC2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.Cl
  • InChI=1S/C22H25NO3/c1-23-18-12-14-19(23)20(15-13-18)26-21(24)22(25,16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-20,25H,12-15H2,1H3/t18?,19?,20-/m1/s1

CS-27349, or L-2-α-tropinyl benzilate, is an experimental incapacitating agent. It acts as an antagonist to muscarinic acetylcholine receptors, causing delirium. It has 37% of the potency of the related compound 3-quinuclidinyl benzilate (BZ) in producing peripheral effects, but 85% of the potency in producing central effects. The mean dose required to incapacitate subjects was 1.2 times that of BZ.[1] It has not been in use since the 1970s, and there have been no publications about its effects or long-term toxicology since then.[2]


  1. ^ Ball JC (2015). "Dual Use Research of Concern: Derivatives of 3-Quinuclidinyl Benzilate". Military Medical Science Letters. 84 (1): 2–41. doi:10.31482/mmsl.2015.001.
  2. ^ Assessment of Potential Long-Term Health Effects on Army Human Test Subjects of Relevant Biological and Chemical Agents, Drugs, Medications and Substances (PDF) (Report). Ho-Chunk Technical Solutions Healthcare Division. February 29, 2016. Archived (PDF) from the original on December 25, 2020.